Millennium Management LLC Acquires 383,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Millennium Management LLC lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 56.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,065,508 shares of the company's stock after acquiring an additional 383,634 shares during the quarter. Millennium Management LLC owned 1.25% of Syndax Pharmaceuticals worth $21,875,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of SNDX. nVerses Capital LLC bought a new position in Syndax Pharmaceuticals during the 2nd quarter worth approximately $33,000. CANADA LIFE ASSURANCE Co increased its stake in Syndax Pharmaceuticals by 28.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company's stock valued at $171,000 after purchasing an additional 1,587 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company's stock worth $187,000 after purchasing an additional 1,312 shares during the period. EntryPoint Capital LLC lifted its position in shares of Syndax Pharmaceuticals by 487.1% in the 1st quarter. EntryPoint Capital LLC now owns 8,636 shares of the company's stock worth $206,000 after buying an additional 7,165 shares during the last quarter. Finally, Seven Eight Capital LP acquired a new position in shares of Syndax Pharmaceuticals in the 1st quarter valued at about $229,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SNDX. Stifel Nicolaus raised their target price on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday, June 26th. JPMorgan Chase & Co. cut their target price on Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Scotiabank lowered shares of Syndax Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, June 14th. Jefferies Financial Group assumed coverage on shares of Syndax Pharmaceuticals in a research note on Friday, June 28th. They set a "buy" rating and a $37.00 target price for the company. Finally, Bank of America lifted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.30.

Syndax Pharmaceuticals Trading Up 0.7 %

Shares of Syndax Pharmaceuticals stock traded up $0.13 during trading on Friday, hitting $18.82. The stock had a trading volume of 559,815 shares, compared to its average volume of 1,272,483. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34. The business has a fifty day moving average of $19.69 and a two-hundred day moving average of $20.85.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.11. The business had revenue of $3.50 million during the quarter. The business's revenue was up 3499999990.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.64) EPS. On average, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).